Maneesh R. Jain, MD

Articles by Maneesh R. Jain, MD

The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan

December 4th 2024

"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.

Latest Updated Articles

The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan
December 4th 2024

Maneesh R. Jain, MD

Articles by Maneesh R. Jain, MD

The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan

Latest Updated Articles

Trending on Urology Times

FDA approves Titan Prime Inflatable Penile Prosthesis

Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617

FDA updates in urology: May 2026

FDA approves cefepime and zidebactam for complicated UTI

PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk